about
sameAs
Effect of interleukin 6 -174G>C gene polymorphism on opioid requirements after total hip replacement.Influence of variation in the catechol-O-methyltransferase gene on the clinical outcome after lumbar spine surgery for one-level symptomatic disc disease: a report on 176 cases.Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.Temperament as a modulating factor of pain sensitivity in combat sport athletes.TNF-α concentrations in pre-operative synovial fluid for predicting early post-operative function and pain after fast-track total knee arthroplasty.The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors.Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.Association study of GATA-2 transcription factor gene (GATA2) polymorphism and Parkinson's disease.Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population.The G allele of MMP12 -82 A > G promoter polymorphism as a protective factor for COPD in Bulgarian population.Analysis of LINGO1 (rs9652490) polymorphism in sporadic Parkinson's disease in a Polish population, and a meta-analysis.Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.Association between CRP gene polymorphism 717A/G, C-reactive protein and neurological deficit in ischemic stroke.The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.Pain perception and cardiovascular system response among athletes playing contact sports.Can we talk about CD4+CD28- lymphocytes as a risk factor for ischemic stroke?Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.Effects of common functional MMP12 gene polymorphisms on PD in a Polish population.IL17A and IL17F Gene Polymorphism Association with Psoriasis Risk and Response to Treatment in a Polish Population.Analysis of MDR1 haplotypes in Parkinson's disease in a white population.Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients.Risk factors of stroke and -717A>G (rs2794521) CRP gene polymorphism among stroke patients in West Pomerania province of Poland.Catechol-oxide-methyltransferase (COMT rs4680:G>A) gene polymorphism does not affect analgesics’ demand after elective hip replacementIL6−174G>C polymorphism is associated with an increased risk of psoriasis but not response to treatmentMitochondrial transcription factor A variants and the risk of Parkinson's diseaseInterleukin-10 Gene Polymorphism in Parkinson's Disease PatientsCARD15 variants in patients with sporadic Parkinson's diseaseBDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's diseaseAssociation of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s diseaseInterleukin-10 (IL10) and tumor necrosis factor α (TNF) gene polymorphisms in Parkinson's disease patientsPolymorphism in semaphorin 5A (Sema5A) gene is not a marker of Parkinson's disease riskAnalysis of LRRK2 G2019S and I2020T mutations in Parkinson's diseaseThe effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's diseaseN-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish populationThe impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease
P50
Q37116445-D2AC0B97-C6C9-48F4-8690-C36B1875614BQ37502728-B2F3DA25-4EB6-45C4-9BEA-8CAEF7259236Q37583417-3686B823-9EE6-42E6-9151-210B90A65753Q39311862-93634742-A73D-4759-B700-25780E76DDC8Q39383480-16687E87-3C91-4C40-861B-F8AEDDC30D0DQ42510131-D7F62892-F054-439A-B5E4-CCBD8A48E0BCQ43136378-63020A01-CDE8-4AF6-9C84-303ABFC64183Q43253254-842B6CAA-5CB2-4094-BAB9-09BFA0A1873FQ43676244-3C4C937C-88D3-4D07-A132-8897B2DAA5E9Q43926090-16ABDA7F-3235-4C46-84F1-3297976469B1Q44082491-48999B60-60AB-4F2D-A636-98FFBDAE40CFQ44094854-4DE8157F-B977-4A90-8575-01F5EA895795Q44568240-4EA1157F-EFDE-4F31-B503-C36C86638918Q46433214-D366C4EC-CE5E-4AE3-AB1D-0D6834584360Q47398422-4A8D19F2-765C-4B3D-943D-17BCF5F39973Q48177039-6BC194EB-AA64-44CF-824A-E4EA56F1F51CQ48320745-1BAEA422-B9DE-4862-96DA-C84D32AA3427Q49896302-35C15520-F6E2-4307-9B28-C3EE7350CFB8Q50558234-88439FB7-A546-4839-A0FC-F127AB03CAD6Q51534960-828F53CD-DE79-4E63-8C1F-0C792E9EA5B0Q51984294-FD03B3EA-50FD-4794-BBCD-834B8D3D61F1Q53855921-9F4E9871-04C1-4BB6-AD7A-D161C4B1C8ADQ54217803-032FE0E4-18DF-4565-9D6F-6F60DB2851FBQ61945727-B1D12819-A2D8-414E-BC03-53D2C64AB10BQ61945742-40A9B228-A02F-4E74-BDF7-E38A27D986DBQ61945766-888EDB9B-71AE-4CF1-B2CA-7D9A9D8C1FDEQ61945779-B4F5D1C7-073A-420D-9B5B-B183D479385FQ61946720-89F099C9-D4E7-429D-AE10-0E81F8ED3B45Q62588894-A7ECCDD8-BCD9-49CB-8CAB-016985BA7BC0Q62588906-A408C150-D22F-4030-A52A-2DB3C3F275C9Q62588917-6458787D-0E2F-4BF9-9492-47C1AD3E8D0FQ62588919-216C05FA-A942-4B39-8BEF-E60E8C6CC9F0Q62588920-0109F067-18AF-44F4-87A8-7ABE2041320AQ62588922-9B2C9F78-1D54-4F22-9EE0-E909A7C1C4C3Q62588924-582D7B2F-79A3-4D39-8853-7E58DE17C605Q64870008-5D7B0D75-66E5-4074-9763-C139786520C2
P50
description
Polish pharmacologist
@en
Pools onderzoekster
@nl
hulumtuese
@sq
polska farmakolog
@pl
հետազոտող
@hy
name
Monika Białecka
@ast
Monika Białecka
@ca
Monika Białecka
@cs
Monika Białecka
@en
Monika Białecka
@es
Monika Białecka
@gl
Monika Białecka
@hr
Monika Białecka
@hsb
Monika Białecka
@it
Monika Białecka
@nl
type
label
Monika Białecka
@ast
Monika Białecka
@ca
Monika Białecka
@cs
Monika Białecka
@en
Monika Białecka
@es
Monika Białecka
@gl
Monika Białecka
@hr
Monika Białecka
@hsb
Monika Białecka
@it
Monika Białecka
@nl
altLabel
Monika Anna Białecka
@pl
prefLabel
Monika Białecka
@ast
Monika Białecka
@ca
Monika Białecka
@cs
Monika Białecka
@en
Monika Białecka
@es
Monika Białecka
@gl
Monika Białecka
@hr
Monika Białecka
@hsb
Monika Białecka
@it
Monika Białecka
@nl
P214
P106
P1153
6602525352
P1412
P1559
Monika Białecka
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-3137-2224
P7859
viaf-102673801